Mirae Asset Global Investments
IONS icon

Mirae Asset Global Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Mirae Asset Global Investments’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Sell
7,867
-1,162
-13% -$87.4K ﹤0.01% 947
2026
Q1 		$678K Buy
9,029
+763
+9% +$60.2K ﹤0.01% 892
2025
Q4 		$654K Buy
8,266
+2,104
+34% +$158K ﹤0.01% 961
2025
Q3 		$403K Buy
6,162
+14
+0.2% +$684 ﹤0.01% 1019
2025
Q2 		$243K Buy
6,148
+829
+16% +$27.1K ﹤0.01% 1028
2025
Q1 		$166K Buy
5,319
+57
+1% +$1.87K ﹤0.01% 1074
2024
Q4 		$189K Sell
5,262
-26
-0.5% -$972 ﹤0.01% 1055
2024
Q3 		$216K Buy
5,288
+930
+21% +$43.3K ﹤0.01% 1076
2024
Q2 		$206K Sell
4,358
-10,723
-71% -$440K ﹤0.01% 1044
2024
Q1 		$613K Buy
+15,081
New +$719K ﹤0.01% 1812
2023
Q4 		– Sell
-12,042
Closed -$546K – 2572
2023
Q3 		$546K Buy
12,042
+129
+1% +$5.32K ﹤0.01% 1837
2023
Q2 		$489K Sell
11,913
-3,658
-23% -$141K ﹤0.01% 1962
2023
Q1 		$557K Buy
+15,571
New +$585K ﹤0.01% 1868
2021
Q4 		– Sell
-6,599
Closed -$221K – 1659
2021
Q3 		$221K Buy
+6,599
New +$249K ﹤0.01% 1665
2021
Q2 		– Sell
-7,772
Closed -$350K – 1716
2021
Q1 		$350K Sell
7,772
-772
-9% -$43.1K ﹤0.01% 1379
2020
Q4 		$483K Buy
8,544
+311
+4% +$15.5K ﹤0.01% 1325
2020
Q3 		$391K Buy
8,233
+3,158
+62% +$175K ﹤0.01% 1267
2020
Q2 		$299K Buy
5,075
+554
+12% +$30.8K ﹤0.01% 1295
2020
Q1 		$214K Sell
4,521
-332
-7% -$18.5K ﹤0.01% 1295
2019
Q4 		$293K Buy
4,853
+248
+5% +$14.8K ﹤0.01% 1354
2019
Q3 		$276K Buy
4,605
+217
+5% +$14.1K ﹤0.01% 1330
2019
Q2 		$282K Buy
4,388
+129
+3% +$9.12K ﹤0.01% 1295
2019
Q1 		$346K Buy
+4,259
New +$275K ﹤0.01% 1156
2016
Q1 		– Sell
-4,215
Closed -$261K – 492
2015
Q4 		$261K Buy
+4,215
New +$227K 0.01% 409

Other funds holding IONS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments's IONS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Ionis Pharmaceuticals (IONS) stake by 13% in Q2 2026, selling an estimated $87.4K and leaving 7,867 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

Mirae Asset Global Investments first reported a position in IONS in Q4 2015 and has held it in 24 quarters since. The position peaked at $678K in Q1 2026. 240 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Mirae Asset Global Investments held 7,867 shares of Ionis Pharmaceuticals worth $624K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,162 Ionis Pharmaceuticals shares in Q2 2026, an estimated $87.4K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #947 holding.
  • Mirae Asset Global Investments first reported a position in Ionis Pharmaceuticals in Q4 2015 and has held it in 24 quarters since.
  • Mirae Asset Global Investments's Ionis Pharmaceuticals position peaked at $678K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.